Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

Provided is a novel Bifidobacterium strain capable of utilizing xylans. Bacteria belonging to the genus Bifidobacterium having a xylanase gene on a genome.

Particularly effective prebiotic-probiotic combinations including a novel probiotic, B. longum subsp longum, and XOS and B. pseudocatenulatum with Xylo-oligosaccharides are provided, together with methods of identifying synergistic probiotic-prebiotic combinations. Additionally, kits comprising the probiotic(s) and prebiotic(s) are also provided.

The combination of specific immunoglobulins plus activated Bifidobacteria strains or other beneficial bacteria is described with the designed efficacy to colonize unstable microbiome communities in humans or other animals, restoring the keystone Bifidobacteria strains or other beneficial bacteria to compositional and functional importance in the intestine and improve overall health and reduce pathogenic infections in the host. Secretory immunoglobulin A (SIgA), when bound via specific glycans to select commensal bacteria grown on human milk oligosaccharides (HMOs), enhances the colonization potential of commensals through protection from intestinal digestion, enhancing attachment, and dampening host immune response.

Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

A freeze-dried nipa palm powder obtainted by mixing (75-100) part of a sap of inflorescence stalk with (0-25) part other ingredients, then freezing said sap of inflorescence stalk with said other ingredients in frozen molds using an individual quick freezer (IQF) at temperature from −25° C. to −29° C. to obtain frozen sap of inflorescence stalk blocks, and freeze drying frozen sap of inflorescence stalk molds at a pressure of 7.8948×10.sup.−4−1.3158×10.sup.−3 atm for 48 hours. The freeze-dried nipa palm powder such as multi-purpose food products that can be used not only as directly, or dissolved in water such as a beverage, but also as a health-promoting functional food, improve immunity, skin care, and beauty for users.

Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

An object of the present invention is to provide an agent for decomposing an opioid peptide or composition for decomposing an opioid peptide that does not restrict dietary habits, does not provide side reactions, even if it is daily used, and thus can be continuously used without any worries. The object is achieved by an agent for decomposing an opioid peptide or composition for decomposing an opioid peptide, pharmaceutical composition for decomposing an opioid peptide, or food or drink composition for decomposing an opioid peptide containing a Bifidobacterium bacterium, a culture of the bacterium, and/or a processed cell product of the bacterium as an active ingredient.

Particularly effective prebiotic-probiotic combinations including a novel probiotic, B. longum subsp longum, and XOS and B. pseudocatenulatum with Xylo-oligosaccharides are provided, together with methods of identifying synergistic probiotic-prebiotic combinations. Additionally, kits comprising the probiotic(s) and prebiotic(s) are also provided.

Consumption of resistant potato starch results in changes to the gut microbiome in elderly adults, resulting in a healthier gut microbiome profile. Furthermore, consumption of resistant potato starch stimulates an increase in Bifidobacterium abundance in all individuals and also reduces levels of E. coli and Shigella. Furthermore, consumption of MSPrebiotic increased the relative ratio of butyrate in the elderly and significantly reduced the use of stool softeners in the elderly.